EMN vs STRO · P/E 21, rev $9.38B vs rev $62.0M
Eastman Chemical Company (EMN) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
EMN currently screens at market cap $8.21B and trailing P/E 20.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the EMN and STRO stock pages for the full models.
Not investment advice.